Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fantasy:
NAVB is only up because I have stopped shorting it. I am currently short 4.12 million shares of NAVB and am fresh out of shares to short. I'm scared to death that the company may be bought out tomorrow North of $10 per share and I could lose close to $35 million when such happens. I post with every intention of holding down NAVB because I know that it has so much potential even a fool should be buying.
REALITY:
My patience is gone with Navidea management. Yes, the pps is trending up, but as far as I'm concerned, 1.62 is a far cry from where the stock belongs and a far cry from where I am even. Q2 numbers are not expected to be good by anyone, though Q3 numbers are expected to be solid. Everything else is nonsense. Let's see what July brings...
I made my bet too, Boo..most of it, right before Crede between 2.75 and 2.99. There is no justice with this stock (and nor will there be). But the morons and the company may yet be dealt with someday.
All of this talk about Manocept being 2-3 years out, or even longer, is absolutely sickening. I understand the shorts more and more - another share offering will be need IF Manocept takes even 12 months to really develop. Wonderful!
NAVIDEA IS GARBAGE. Few insider buys, yet Brent Larson is selling. I don't give a damn about his alleged tax purposes, he is selling and NOT BUYING.
It is time for a shareholder lawsuit and major changes in this company.
I wonder if NAVB is the first stock in history to have a short interest that is four times as big as the outstanding share count.
Unless there is a buyout above 2.11 per share, this joke of a company may never see a pps above 2.11 EVER EFFING AGAIN.
As expected, NAVB stalls before it gets going. Told ya. :(
Let's see if the stock is trading above 1.53 after 10:00AM. Will NAVB even see 1.50 tomorrow or 1.60? We have seen great after hours news before with a high after hours pps that doesn't get seen the following day. Up .22 on low volume AH - wow! But I'm not counting any chickens yet...
I just sent a Facebook message to Rosalind Primmer (Thom Tulip's wife) and his beloved son (Brynn Tulip) that if Thom is looking for a job, McDonald's is hiring...the thought of a destructive deadweight like Thommyboy getting a huge severance makes me want to buy a new roofing hammer.
Ocata, even half of your revenue projection would rocket NAVB out of the toilet and even generate some much belated respect for Pykett, Tulip, and the still employed Navidea tool crew. The trouble is, your projections are in line with projections we had prior to Lymphoseek approval...and as far as I am concerned, there must be some downside to Lymphoseek that is keeping it so underused. Is it the price for a single Lymphoseek dose? I don't know. The stock price is the main thing I watch and the stock price is abominable!
I don't like the idea of these 12 Lymphoseek sales representatives unless they EACH generate a minimum 10-15X their total gross pay in Lymphoseek sales BY THE END OF Q1 2016 at the effing latest. With our luck, Lymphoseek sales will be down with their efforts and they will each receive 1,000,000 free NAVB shares accordingly. Sorry for the ridiculous sarcasm, but Navidea continually rams it to shareholders, and I AM ONE SHAREHOLDER THAT IS GETTING MIGHTY TIRED OF THE ABUSE.
The two recent RIGHTFUL THOUGH BELATED TERMINATIONS of Tulip and Reininger will free up a considerable amount of cash. Gonzalez should have eliminated these two and Larson effective 1/1/15...Brent Larson should be next. His termination would generate an enormous new confidence in shareholders and investors who have never heard of Navidea that didn't have to watch the 3.00+ share price dwindle to .97...I am one shareholder not doing handsprings over 1.42, or even 2.00.
Q3 numbers might show considerable improvement over Q1 and Q2, but even "improvement" isn't enough. I want a $10 million quarter effing yesterday and frankly, it just don't feel like such is a coming...I like your optimism Ocala, I just don't share it - I hold 30,400 shares of this garbage company and something DAMN SURE NEEDS TO CHANGE QUICKER THAN FAST.
I'm impressed with you island man. You post very seldom here and have now come alive to bash my posting. The only thing dumber than owning 1,000 shares of NAVB is owning 2,000. Remember that, tool.
Palantir is a disillusioned long, I am a long ready to take matters into my own hands. Islander shows up to make a new post every nine months like a new baby. How insightful to question my posts. Instead, question the company that destroyed over $100 million of shareholder money with the Crede deal and abominable Lymphoseek sales so far, along with at least ten other major missteps. They should have been smart enough to know from the get go that the product would not sell itself. We damn well better see some huge news when July comes. When do Navidea executives start working toward shareholder value?
Palantir, you might want to keep in mind that the precious company valued itself at 2.11 per share for the precious Crede deal and we have been no where near that disgusting pps for quite some time. I don't know if you are really Larson or Pykett in disguise, but any shareholder here should be angry and feel raped and abused like we have certainly been for 2 years now!
Brent Larson should be gone as well. Many biotechs move up when the fat is trimmed. As for NAVB, we lost ground today. Wonderful!
DDbuyer said today, "They're all relevant. The conference starts June 30th. We don't have long to wait now... and there are other things in the works. Things will begin to heat up..."
IF he's right, then it's about effing time. I for one though, DO NOT like the idea of tossing hundreds of thousands of more dollars out the window to pay severance benefits to deadweight garbage that hurt the company and shareholders. Did the company borrow $60 million just to make sure that everyone gets a huge severance bonus if the company folds up? I want to see and hear some rock solid effing Manocept news effing yesterday.
It really is nice to see an up day, but no one here should kid themselves. 1.44 is disgusting considering where NAVB was in Summer 2013 - right around $3.00. We are a long ways from where we belong. In fact, we are trading well below where we were before there was even a Lymphoseek NDA.
An up day is nice to see though, especially on low volume like today.
Will the gains hold at all? My money says not likely. 1.34 close on Friday?
1.15 today? .94 tomorrow? Will Larson and Gonzalez laugh it up with Tulip at their 9:25AM coffee break with jokes about Navidea shareholders? I called Brent Larson this past Friday to discuss the ridiculous and disgusting performance of Navidea stock. Instead of discussing my concerns, he shared the latest inside company joke with me that really cracked up himself and Gonzalez on the golf course a few days earlier:
LARSON: "What's dumber than owning 50,000 shares of NAVB stock?"
GONZALEZ: "I don't know. I really can't think of anything."
LARSON (laughing uncontrollably): "Owning 100,000 shares! LOL."
250,000 shares of short covering last time around is nothing. How amazing that there has been no positive update on anything in 2015 so far and the shorts are not covering anything in substantial quantity either. This continues to look more and more like one of the best stock frauds in history.
No update for 4694 is anywhere in sight and it appears ever more likely that nothing but more evidence of Navidea wastefulness will come out of the complete divestiture of it, just like 5001.
The 12 new sales representative for Lymphoseek with certainly dent the company's strapped finances further and further (which is no doubt the real plan) while they will simultaneously increase sales only 3-4% tops. What a ridiculous management team Navidea has. What a ridiculous scam this is. I'm surprised they didn't hire 4,000 Lymphoseek sales representatives - they could have achieved victory for the shorts and bankruptcy much sooner than with only 12 more overpaid employees...The torture for us all continues.
The bs continues. The pps is 1.29. We need solid news that 4694 was not another colossal waste of company capital, we need news that Manocept is real, news that Manicept is moving forward, and news that Manocept is going to build shareholder value. So far, nothing. I envy the investor that has never heard of NAVB and I feel a great deal of sympathy for ANYONE that bought this garbage stock in late 2014 on the run to 2.03. Pathetic pull back here, as always.
There are no buyers in sight and we have lousy Q2 2015 numbers to look forward to, the total divestiture if 4694 to look forward to (at a HUGE financial loss to the company), the first of many Manocept letdowns should be released soon, and even more unimaginable bad news that Brent Larson and Thom Tulip shared with their effing short friends 2-3 years ago. The patience of every investor of this stock is truly amazing. The next shareholder meeting will be interesting.
If a buyout from a major pharmaceutical was offered at 3.40 per share, does anyone else agree that Brent Larson would insist on selling the company for 0.75/share?
After all, he owes it to his short friends to ram it to the retail shareholder eternally. Of that, he had done a marvelous job! More free shares for Brent NOW!
Thinking going through this summer we'll know quite a bit more.
Congratulations boo. You can celebrate when the stock hits 1.50 again. You'll be up 4% on your position and the rest of us will only be down 45% on ours.
The Oldtimers go together for a party when NAVB reached 1.00 six or seven years ago. Looks like another 1.00 party could happen anytime...Disgusting.
The shorts are going to get this stock under 1.00 and will cover there BEFORE Manocept is ever launched. It is becoming exceedingly clear to me that the company is protecting the shorts through continual mismanagement. The shorts are not covering because their day is still coming. Oodles of bad news is on the horizon. When the company releases the details on just how bad the 4694 abandonment is, followed by lousy Q2 2015 numbers, the stock is likely to visit .75 or less (and stay there for months). The shorts HAVE ALREADY BEEN ASSURED THAT BAD NEWS LIKE THIS OR EVEN WORSE NEWS IS COMING - NO REASON TO COVER ABOVE 1.00.
The shorts have absolutely nothing to fear.
Navidea executives, they should have much to fear...
Larson and Gonzalez can't stand it that the pps is holding 1.25. They need it to be much, much lower for their short friends. Rumor is, they plan to announce the complete divestiture of 4694 and 1800 at the next shareholder meeting. Moreover, to really ram it to us, they will specify that $25 million was thrown away temporarily pursuing these two phantom pipeline products. The next day, more financing will be announced.
It looks more and more like all financing that Navidea secures does nothing more than to secure the jobs of men and women at Navidea - men and women who deserve huge pay cuts or outright dismissal. This situation in unacceptable!
I hope something drastic and tragic happens at the next shareholder meeting. We continually get pissed on and shit on by management and even the Oldtimers are too stupid to see it. The Oldtimers must have been fortunate enough to sell out ahead of the Crede deal. Good for them. This stock is going to have significant difficulty seeing 1.50 again this year. May the shareholder meeting be a bloodbath and may Larson, Tulip, and Gonzalez get what they have coming to them!
More bad news and terrible financing deals are ahead. Lymphoseek isn't selling and there is no fix. Manocept is a Pykett discovery...just like Crede. Enough said.
Why was this financing necessary when Navidea already has the Platinum line of credit in place? The company is losing money, credibility, and investors very fast. I am more convinced than ever that not only will NAVB NOT SEE 2.00 again, the short interest is going to start building further as the shorts start to finish this garbage stock and company off once and for all.
Just once, I'd like to hear Gonzalez or whoever the hell is speaking for the day use the expression "shareholder value." I guess they cannot use such an expression since a 14% loan eliminates all chances of Navidea being profitable for at least 5-7 years. I didn't even want to post this reality, but others are seeing the same harm to shareholders, so let's face the newest reality of Navidea effing their own shareholders. What's next, a reverse split? Two Crede deals on consecutive days? Terminate Gonzalez, JUST TO WASTE $1,000,000 in severance to do so?
I guess they can't use the term "shareholder value" because they are far more concerned with getting more free shares without merit than doing anything to restore the value they DESTROYED with the Crede deal. Don't forget, the company valued itself at 2.11 with the precious Crede deal and we are light years and decades away from that pathetic pps right now. 2.11 is garbage level considering where many of us bought in.
No wonder the shorts are covering little or no shares in their positions. All they have to do is give it another month and watch the next company action aimed at harming the retail shareholder.
I hope someone out there deals with them all at the next shareholder meeting. :) We are a long way from $2, let alone $2.50 or better. The nonsense needs to be put to a stop. Rumor is, Larson offered 18.5% interest to the financing institution, but they refused knowing that they were already raping us sufficiently at 14%.
And the new salesforce is a joke AS ARE ALL SALESPEOPLE EVERYWHERE IN ALL MARKETS. In 2015, NO ONE wants to be bothered by sales representatives. The short interest is bound to increase now. With no profitability in the next decade, the shorts have nothing to worry about at all. Wonderful!
The shorts have already been informed of the following things by insiders:
1) There will be AT LEAST one more share offering within the next 2 years.
2) Manocept is purposefully going to fail. This means, that even with FDA approval, the company will fail to market Manocept products like they did with Lymphoseek.
3) They shorts were also informed that that 5001 and 4694 were never really going to be honestly developed by the company EVEN BEFORE THE COMPANY PURCHASED 4694 and 5001- and even better, both products were a great way to waste the Crede deal money WHICH SIMULTANEOUSLY CRUSHED THE SHARE PRICE.
4) The shorts were told all along years ago that RIGS or 1800 of whatever the hell else you want to call it, was NEVER going to be pursued either.
5) The shorts were told five years ago that the company KNEW that Lymphoseek would be a tough sell going through Cardinal alone, and that shorting the stock perpetually would have a fine pay day in 2015 or 2016.
Why do I say all of this? THERE IS NO OTHER EXPLANATION FOR HOW A PHARMACEUTICAL COMPANY COULD APPEAR TO HAVE SO MUCH GOOD GOING FOR IT AND SIMULTANEOUSLY HAVE A SHORT INTEREST OF 30,000,000 SHARES. Earnings will be bad for Q1 and Q2 2015. MARK THIS POST RIGHT NOW. $2 million or even $3 million in revenue for a quarter is garbage level.
I'm not holding my breath for Q3 2015, but I believe that Q3 might be better than Q1 and Q2 combined.
Regardless, it won't take many more screw ups or let downs to really destroy this stock all the way...and bonus shares are still being awarded?! Are you F kidding me?!
Interesting spike up to 1.40 yesterday. 1.40 is disgusting territory for this stock, as is 2.00. Have no fear though. NAVB couldn't hold 1.40 and we're right back in the shitter today at 1.30. Great job Gonzalez. Choke on a taco, Paco!
DDbuyer has said the onion layers keep getting peeled...
The only thing getting peeled here is the retail shareholder, day by day, cent by cent.
If Manocept was worth BILLIONS like Goldberg said one year ago, NAVB would be trading for at least $4 per share, if not, much higher. This nonsense is disgusting. Lousy sales on 5/12 will be devastating and I believe the shorts are already aware of just how bad earnings will be and are hammering away right now. By getting the pps under 1.00 next Tuesday, even the official Manocept spinoff announcement won't get the pps back above 1.50.
Don't forget that when the lousy Q4 report came out, we got a double dose of bad news that included $500,000 in wasted Lymphoseek inventory. I wonder how many free shares of NAVB Brent Larson received for that mess up.
We have all been had. Let the shareholder lawsuits and major change in control at Navidea begin.
1.23 now...WONDERFUL!
NAVB is trading more like Manocept is already running into major problems and the word is out AND Lymphoseek sales will be as dreadful as ever. 5001 was already abandoned with precious company money wasted. Let's see just how bad the company wastes resources when they announce their LACK OF PLANS for 4694.
A new board and all new executives are necessary now. This stock is headed under 1.00 and is apt to stay there for a long long while!
I called it! 1.25 this week and lucky us, we got to see 1.24 today. Can the stock hold 1.00 next week, regardless of earnings? Probably not.
I am considering a phone call to Gonzalez's office. He may not take calls, but his secretary will undoubtedly share my message with him from the sharp tone of my voice and the clear message that I mean business.
NAVB is at 1.27 because of poor sales and the abandonment of 5001. I can hardly wait to see how bad things get after next Tuesday 5/12 when more poor sales are revealed and the similar abandonment of 4694 is finally revealed.
Shareholder lawsuit sound good to anyone?
An article coming within 18 months?
Taken from:
MEDICAL NEWS TODAY
June 19, 2016
"LYMPHOSEEK and NAVIDEA, the treatment and company that never were"
Three years ago, Navidea (formerly Neoprobe) gained FDA approval for Tilmanocept-99, specifically designed and indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma. Since March 2013 though, sales have only amounted to $9.3 million as the medical community worldwide has simply not taken to the product. "I just don't know what to make of it," said Allen Richards (Navidea's seventh CEO in the past three years) "We were so sure it would become the standard of care. In the end, all we did was fleece investors and create angry shareholders." Brent Larson, a long time Navidea employee was terminated and jailed in September 2015 after it was revealed that he had illegally been feeding insider information to numerous large short sellers of the company for years, albeit to the company's near bankruptcy at present. Adding to Navidea's problems was the failure of NAV5001, NAV4694, NAV1800, and their Manocept Platform. Collectively, the four pipeline products never brought a dime of revenue to Navidea, but cost more than $85 million over the past 5 years. With 1,975,000,000 shares outstanding from five new share offerings since the September 2013 Crede deal, and a current share price of .04, the future of this tiny biotech is more in doubt than ever. Another Crede deal is rumored to be near finalization as this story is being typed.
This garbage stock will see 1.25 this week - and lower when earnings are announced. With a kick in the face update on 4694 like what we got with 5001, this stock will be under a dollar in no time.
NAVB IS A GARBAGE STOCK. I envy anyone who has never heard of it.
I have to wonder: IF AND WHEN THE COMPANY EVER ANNOUNCES PLANS FOR THE MANOCEPT SPINOFF, AND IF THESE PLANS INCLUDE A 1 FOR 1 SHARE IN THE NEW COMPANY FOR EVERY NAVIDEA SHARE OWNED, WILL THE NAVB PPS MOVE UP EVEN A DIME ON THE ANNOUNCEMENT?
This company has succeeded in ruining their shareholders.
More free shares for Larson RIGHT NOW! PLEASE!
I have to wonder: IF AND WHEN THE COMPANY EVER ANNOUNCES PLANS FOR THE MANOCEPT SPINOFF, AND IF THESE PLANS INCLUDE A 1 FOR 1 SHARE IN THE NEW COMPANY FOR EVERY NAVIDEA SHARE OWNED, WILL THE NAVB PPS MOVE UP EVEN A DIME ON THE ANNOUNCEMENT?
This company has succeeded in ruining their shareholders.
More free shares for Larson RIGHT NOW! PLEASE!
The company is letting the pps slide back toward 1.00 and allowing the shorts a tremendous opportunity to cover WHEN INSTEAD the company SHOULD BE UNVEILING THEIR LONG AWAITED PLANS FOR THE MANOCEPT SPINOFF.
This company is not attracting new buyers with their outright disregard for existing shareholders. I envy those that have never heard of NAVB. I also envy the shareholder that someday takes matters into their own hands in dealing with this joke of a company. Enough is enough.
Today seems like another short covering day specially orchestrated by the company...Will huge blocks of 1-2 million shares go through at the end of the day? The company is saying nothing about the Manocept spinoff (which could benefit the NAVB shareholder) AND IS INSTEAD giving away hundreds of thoussands of UNDESERVED shares to moron management. Larson is lucky I don't live in Dublin!
The company seems much more interested in destroying the share price first to help the shorts cover...predictable and tiresome. Just when things might be looking up, more BS from Larson and company pulls the rug out from under us all.
Larson and the BOD are getting hundreds of thousands more free shares. No wonder the short interest is so high. The shorts know that management is best at creating and maintaining investor perception that the company is going to eternally harm it's own shareholders at all costs.. Zelkuschabo and dennisprice583 are spot on from their weekend posts. 1.47 or less does indeed seem likely.